When asked about the Cipla Indore facility, which has come under the USFDA scanner for manufacturing norms violations, Talati reassures that the facility is not a major contributer to Cipla earnings. Hence this news, he feels should not affect sales.
first published: Feb 23, 2016 01:47 pm
A collection of the most-viewed Moneycontrol videos.
You are already a Moneycontrol Pro user.

